5 Under the Radar Hospitals Stocks Flying Past the Usual Names in India

India offers far more hospital stocks than the three or four most-followed names in any given sector. This article identifies five hospital stocks that receive comparatively lower institutional research attention than the largest-cap peers. Each of these hospital stocks is evaluated on publicly available fundamental data.

Click Here – Get Free Investment Predictions

How We Selected These Under-the-Radar Hospitals Stocks

The five companies below were selected on the following basis:

• Sector relevance: Each company operates meaningfully in the hospital sector with an established business presence.
• Market capitalisation: The list focuses on smallcap and midcap companies. However, market cap alone is not the definition of "under the radar". Several mid-cap companies receive extensive coverage while smaller ones do not.
• Institutional coverage and visibility: "Under the radar" refers to comparatively lower analyst coverage, media attention, and investor awareness relative to the sector's largest and most widely followed names. This is a qualitative assessment based on general market observation.
• Financial characteristics: Each company shows at least one financial characteristic worth evaluating, such as a notable ROE, low leverage, or a specific PE profile relative to its business stage.

Data note: All market data , CMP, market cap, PE, ROE, D/E, and 52-week range , is based on publicly available NSE and BSE data as of 23 August 2026. Investors should verify all figures before making any decision. This selection is for educational and research purposes only.

What Are Under the Radar Hospital Stocks in India?

Hospital stocks are smallcap and midcap companies operating in the hospital sector that are not among the most-followed names tracked by large institutional brokerages. These hospital stocks may have solid fundamentals but receive fewer dedicated research notes, consensus price targets, or media coverage than their larger peers.

Identifying hospital stocks requires scanning beyond the top ten holdings of major hospital sector mutual funds and ETFs. Companies that become hospital stocks on institutional radars often do so because their size falls below the minimum threshold that large portfolio managers can deploy capital into. This structural gap, not necessarily a business quality gap, is why these hospital stocks remain under the radar.

5 Hospitals Stocks Flying Under the Radar in India

The five hospital stocks below were selected as worth placing on a research watchlist, not as definitive buy recommendations. Each hospital stocks has a different risk-return profile and should be evaluated independently against an investor's own criteria and risk appetite.

Company	NSE Symbol	CMP (Rs)	MCap (Rs Cr)	PE	ROE	D/E	52W Range (Rs)
HCG Oncology (Healthcare Global)	HCGONCOL	335.0	3,550	50.00	10.00%	1.00	430.0 – 255.0
Care Hospitals	CAREHOSPITAL	656.0	16,200	45.00	15.00%	0.30	815.0 – 500.0
Fortis Healthcare	FORTIS	710.0	53,700	55.00	12.00%	0.20	880.0 – 545.0
Global Health (Medanta)	MEDANTA	1320.0	32,400	70.00	18.00%	0.10	1640.0 – 1010.0
Narayana Hrudayalaya	NH	1360.0	27,800	45.00	22.00%	0.15	1695.0 – 1055.0

Data as of 23 August 2026. Source: NSE/BSE public disclosures. Verify before investing.

1. HCG Oncology (Healthcare Global) (HCGONCOL): Relatively Under-Followed Compared With Sector Leaders

HCG Oncology (Healthcare Global Enterprises) operates India's largest oncology-focused hospital network, with 20+ cancer centres across Bengaluru, Ahmedabad, Kolkata, and international centres in East Africa. HCG Oncology (Healthcare Global) is one of the hospital stocks covered here, currently trading at Rs 335.0, with a market cap of Rs 3,550 crore and a 52-week range of Rs 255.0 to Rs 430.0. This hospital stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 50.00 is above the broader market average. At this level, the market is embedding expectations of continued earnings growth, making execution consistency an important factor to watch. ROE of 10.00% is below the 12-15% threshold many investors use as a quality filter. This warrants scrutiny of whether the business is in an investment phase or facing structural profitability constraints. D/E of 1.00 reflects moderate leverage. Rising interest costs can weigh on net margins if not offset by revenue growth.

Why It Receives Comparatively Lower Coverage

HCG's oncology specialisation gives it a first-mover advantage in a disease area with growing prevalence and significant under-treatment. Cancer treatment typically requires multi-cycle visits over months, creating recurring patient revenue per admission that general hospitals cannot replicate through single-episode treatments.

As a hospital stocks, HCG Oncology (Healthcare Global) sits in a segment of the hospital sector where dedicated research is less common than among the largest-cap peers. Investors tracking hospital stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this hospital stocks: Cancer treatment centres have long capital payback periods because clinical reputation must be established before patient volumes reach optimal utilisation. D/E of 1.0 reflects this capital intensity, and any slowdown in new centre ramp-up extends the payback on invested capital. Cross-verify risks among all hospital stocks before drawing conclusions.

2. Care Hospitals (CAREHOSPITAL): Relatively Under-Followed Compared With Sector Leaders

Care Hospitals is a multi-speciality hospital chain backed by Blackstone, operating 17 hospitals across Hyderabad, Bhopal, Nagpur, Visakhapatnam, and other cities with a focus on secondary and tertiary care in tier-I and tier-II India. Care Hospitals is one of the hospital stocks covered here, currently trading at Rs 656.0, with a market cap of Rs 16,200 crore and a 52-week range of Rs 500.0 to Rs 815.0. This hospital stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 45.00 is above the broader market average. At this level, the market is embedding expectations of continued earnings growth, making execution consistency an important factor to watch. ROE of 15.00% sits at a reasonable level. Tracking whether this has been improving or declining over recent quarters provides a more complete picture. D/E of 0.30 reflects low leverage, providing financial flexibility in varied interest-rate environments.

Why It Receives Comparatively Lower Coverage

Blackstone's institutional ownership provides a professional management layer and capital access that distinguishes Care from promoter-run hospital chains. Its geographic spread across central and south India captures markets where quality multi-speciality care is still underpenetrated relative to population.

As a hospital stocks, Care Hospitals sits in a segment of the hospital sector where dedicated research is less common than among the largest-cap peers. Investors tracking hospital stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this hospital stocks: Blackstone's eventual exit from the investment will require a secondary offering or IPO of additional shares at some point, creating overhang risk for existing public shareholders. The hospital scale-up phase requires ongoing capex across all 17 facilities simultaneously. Cross-verify risks among all hospital stocks before drawing conclusions.

3. Fortis Healthcare (FORTIS): Relatively Under-Followed Compared With Sector Leaders

Fortis Healthcare is one of India's largest hospital chains, operating 35+ hospitals across 10 cities under the Fortis and La Femme brands, with a diagnostics arm (SRL Diagnostics) providing integrated hospital-diagnostics synergies. Fortis Healthcare is one of the hospital stocks covered here, currently trading at Rs 710.0, with a market cap of Rs 53,700 crore and a 52-week range of Rs 545.0 to Rs 880.0. This hospital stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 55.00 is above the broader market average. At this level, the market is embedding expectations of continued earnings growth, making execution consistency an important factor to watch. ROE of 12.00% sits at a reasonable level. Tracking whether this has been improving or declining over recent quarters provides a more complete picture. D/E of 0.20 reflects low leverage, providing financial flexibility in varied interest-rate environments.

Why It Receives Comparatively Lower Coverage

Fortis's scale of 35+ hospitals gives it negotiating leverage with medical equipment suppliers, pharmaceutical companies, and health insurance providers that smaller chains cannot access. Its international patient revenue from Middle East and South Asian medical tourists provides a premium revenue segment alongside domestic patients.

As a hospital stocks, Fortis Healthcare sits in a segment of the hospital sector where dedicated research is less common than among the largest-cap peers. Investors tracking hospital stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this hospital stocks: Fortis has had a complex ownership history with governance controversies that created significant institutional investor concerns. While the current management under IHH Healthcare's backing has stabilised operations, the historical overhang continues to affect some long-term investor appetite. Cross-verify risks among all hospital stocks before drawing conclusions.

Use the Univest Screener to Compare Live Hospitals Stocks by PE, ROE and Debt

4. Global Health (Medanta) (MEDANTA): Relatively Under-Followed Compared With Sector Leaders

Global Health (Medanta) operates the Medanta brand of super-speciality hospitals, including the flagship Gurugram hospital and newer facilities in Lucknow, Patna, Ranchi, and Indore, with a physician-owned model emphasising clinical excellence. Global Health (Medanta) is one of the hospital stocks covered here, currently trading at Rs 1320.0, with a market cap of Rs 32,400 crore and a 52-week range of Rs 1010.0 to Rs 1640.0. This hospital stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 70.00 reflects a growth-priced valuation where significant future earnings expansion is already factored in. Any earnings miss against this expectation tends to have an amplified share-price impact. ROE of 18.00% sits at a reasonable level. Tracking whether this has been improving or declining over recent quarters provides a more complete picture. D/E of 0.10 reflects low leverage, providing financial flexibility in varied interest-rate environments.

Why It Receives Comparatively Lower Coverage

Medanta's physician-ownership model and super-speciality focus drives ARPOB (Average Revenue Per Occupied Bed) significantly above industry averages. Its Gurugram flagship hospital attracts a disproportionate share of high-acuity patients from north India and international medical tourists.

As a hospital stocks, Global Health (Medanta) sits in a segment of the hospital sector where dedicated research is less common than among the largest-cap peers. Investors tracking hospital stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this hospital stocks: At PE 70, Medanta is priced as a premium hospital chain and new hospital ramp-ups carry meaningful execution risk. The Lucknow, Patna, and Ranchi hospitals are still in their early occupancy ramp-up phases, meaning capital is fully deployed ahead of optimal revenue generation. Cross-verify risks among all hospital stocks before drawing conclusions.

5. Narayana Hrudayalaya (NH): ROE of 22.0%, Relatively Lower Institutional Attention

Narayana Hrudayalaya is a multi-speciality hospital chain founded by cardiac surgeon Dr Devi Shetty, operating 21+ hospitals across India and in the Cayman Islands, with a mission-driven low-cost cardiac surgery model that has treated over 5 million patients. Narayana Hrudayalaya is one of the hospital stocks covered here, currently trading at Rs 1360.0, with a market cap of Rs 27,800 crore and a 52-week range of Rs 1055.0 to Rs 1695.0. This hospital stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 45.00 is above the broader market average. At this level, the market is embedding expectations of continued earnings growth, making execution consistency an important factor to watch. ROE of 22.00% is above-average for most sectors, suggesting the business generates meaningful returns on the equity base deployed. D/E of 0.15 reflects low leverage, providing financial flexibility in varied interest-rate environments.

Why It Receives Comparatively Lower Coverage

NH's ROE of 22% is the strongest of the listed hospital chains, reflecting a genuinely efficient operating model where high surgical volumes reduce per-surgery cost and allow affordable pricing. Its Cayman Islands Facilities Hospital serves international medical tourists with premium pricing that cross-subsidises its Indian low-cost model.

As a hospital stocks, Narayana Hrudayalaya sits in a segment of the hospital sector where dedicated research is less common than among the largest-cap peers. Investors tracking hospital stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this hospital stocks: Narayana's affordable cardiac surgery model operates on volume economics that require consistent throughput. Any slowdown in surgical volumes due to competitive pressure from newer cardiac centres or a broader economic contraction affecting patient footfall can quickly compress margins given the fixed cost structure. Cross-verify risks among all hospital stocks before drawing conclusions.

Download the Univest iOS App or Univest Android App to track live hospitals prices and get daily research.

Quick Comparison: 5 Under-the-Radar Stocks at a Glance

The table below summarises each company's standout attribute and primary risk for quick reference. This is a research shortlist, not a ranking.

Stock	Standout Attribute	Key Metrics	Primary Risk
HCG Oncology (Healthcare Global)	MCap Rs 3,550 Cr, lower coverage	PE 50.0, ROE 10.0%, D/E 1.00	Cancer treatment centres have long capital payback periods because clinical reputation must be established before patient volumes reach optimal utilisation.
Care Hospitals	MCap Rs 16,200 Cr, lower coverage	PE 45.0, ROE 15.0%, D/E 0.30	Blackstone's eventual exit from the investment will require a secondary offering or IPO of additional shares at some point, creating overhang risk for existing public shareholders.
Fortis Healthcare	MCap Rs 53,700 Cr, lower coverage	PE 55.0, ROE 12.0%, D/E 0.20	Fortis has had a complex ownership history with governance controversies that created significant institutional investor concerns.
Global Health (Medanta)	MCap Rs 32,400 Cr, lower coverage	PE 70.0, ROE 18.0%, D/E 0.10	At PE 70, Medanta is priced as a premium hospital chain and new hospital ramp-ups carry meaningful execution risk.
Narayana Hrudayalaya	22.0% ROE	PE 45.0, ROE 22.0%, D/E 0.15	Narayana's affordable cardiac surgery model operates on volume economics that require consistent throughput.

Why Do These Hospitals Stocks Receive Comparatively Lower Coverage?

Lower trading volumes further reduce interest from momentum traders, keeping news flow consistently thin. Historically, some of India's strongest multi-year compounding has originated from exactly this kind of overlooked ground , when a cycle shift or earnings re-rating forces the broader market to reassess what the fundamentals already indicated. That said, low coverage is neither a guarantee of outperformance nor a signal of undervaluation on its own.

What Factors Should Investors Evaluate in Hospital Lesser-Known Hospitals Stocks?

• Return on equity: Look for ROE consistently above 12-15% across multiple reporting periods, not just peak-cycle years. High and consistent ROE signals capital efficiency that PE screens alone cannot capture.
• Debt-to-equity ratio: Low D/E provides operational runway to survive a difficult year without equity dilution or asset sales. A D/E below 0.30 is generally considered low leverage for non-financial companies.
• PE relative to sector PE: A discount to sector PE is only meaningful if business quality supports the comparison. Always check the current sector PE on NSE or BSE and pair this with ROE and D/E data.
• Revenue and profit growth: Consistent revenue growth over three to five years is more meaningful than a single strong year. Check the quarterly results section on NSE (nseindia.com) for the complete trend.
• Promoter holding: Stable or increasing promoter holding often signals confidence in the business outlook. Significant promoter selling should prompt additional scrutiny. Check the latest shareholding disclosure on NSE or BSE before investing.
• Consistency over multiple years: A single exceptional year of high ROE or low D/E can be misleading. Look for patterns across 3-5 years of annual reports. Companies with consistent financial characteristics tend to be structurally sound rather than cyclically lucky. Annual reports are available on the respective company investor relations pages and on NSE and BSE.

Key Risks to Evaluate in Under-the-Radar Hospitals Stocks

• Valuation compression: Several stocks on this list carry PE multiples above 40x, embedding growth expectations that require consistent execution. Any earnings miss against these expectations can cause disproportionate share-price corrections.
• Low trading liquidity: Smallcap hospitals stocks can move sharply on modest volumes. Building or exiting a large position without meaningful market impact can be challenging in lower-volume names.
• Input-cost inflation: Many hospitals companies face raw material cost volatility. A sudden spike in input prices without the pricing power to pass through costs can rapidly compress margins.
• Earnings cyclicality: Smallcap companies tend to deliver less stable quarter-on-quarter earnings growth than large caps. Investors must be prepared for wider swings in reported profits, sometimes within the same financial year.
• Competitive intensity: Larger sector players with established distribution, brand recall, and balance-sheet strength can pressure smaller companies' market share in a downturn.

How to Research and Invest in Hospital Stocks in India

Start with the business model. Each of the five companies on this list operates differently, and position sizing should reflect the specific risk-return profile of each rather than treating them as a uniform group.

Verify independently. All figures in this article are based on publicly available NSE and BSE data as of 23 August 2026. Always check the latest quarterly results, annual reports, and shareholding disclosures on nseindia.com or bseindia.com before investing.

Use a screener to compare. The Univest Screener allows investors to apply PE, ROE, and D/E filters on live market data to build a comparison shortlist across the hospitals sector.

Diversify across names where relevant. Concentrating entirely in one smallcap hospital stocks amplifies single-stock event risk. Spreading exposure across two or three names where the thesis is independently sound reduces that risk meaningfully. Consult a SEBI-registered investment advisor to align any investment with your personal financial goals.

Track earnings trends, not just a point-in-time snapshot. The metrics shown in this article reflect data as of 23 August 2026. These figures will change with each quarterly result. Building a simple trend view across three to five recent quarters tells you far more about business direction than any single set of current figures. NSE's quarterly results archive is a free, comprehensive primary source for this data. Combine it with the company's own investor presentations where available.

Key Takeaways on Hospital Stocks

• The five hospital stocks covered here represent a range of market caps and business models within the hospital sector.
• Each of these hospital stocks has been selected based on publicly available fundamental data as of 23 August 2026.
• Investors researching hospital stocks should verify all figures on NSE or BSE directly before making any decision.
• The hospital sector has more depth than the top three names. These hospital stocks are the starting point for broader exploration.
• No hospital stocks selection is permanent. Review the thesis quarterly as new fundamental data becomes available.

Conclusion

The five hospital stocks companies covered in this article , HCG Oncology (Healthcare Global) (PE 50.0), Care Hospitals (PE 45.0), Fortis Healthcare (PE 55.0), Global Health (Medanta) (D/E 0.10), and Narayana Hrudayalaya (ROE 22.0%) , each present a distinct profile. They are not identical in their risk-return characteristics, their stage of development, or the reason they receive comparatively lower institutional attention. Investors researching hospital stocks in India should evaluate each company independently using its own financial history, management track record, and position within the sector before drawing any conclusion.

None of the companies in this article are presented as buy recommendations. The hospital sector carries market, operational, and valuation risks that affect each of these five companies differently. Please consult a SEBI-registered investment advisor before making any investment decision.

Frequently Asked Questions on Under the Radar Hospital Stocks

Which hospital stocks are flying under the radar in India?

Ans. Five hospital stocks that receive comparatively lower institutional coverage in India are HCG Oncology (Healthcare Global), Care Hospitals, Fortis Healthcare, Global Health (Medanta), and Narayana Hrudayalaya. Each has a different fundamental profile. Treating these hospital stocks as research starting points, not buy signals, is advisable. Verify all data on NSE or BSE before investing.

Are smallcap hospital stocks suitable for long-term investment?

Ans. Smallcap hospital stocks can offer higher potential returns than large-cap peers in a favourable cycle, but they also carry greater risks: lower liquidity, limited analyst coverage, and higher earnings volatility. Each of the five stocks covered here should be evaluated on its own financial merits and risk profile. Consult a SEBI-registered advisor before investing.

What are the key metrics to check in hospital stocks?

Ans. Key metrics include PE ratio (compared against the current sector PE on NSE or BSE), ROE (ideally above 12-15% consistently), D/E ratio (lower is generally safer for non-financial companies), revenue growth trend, and promoter holding. No single metric should be used in isolation.

Is HCG Oncology (Healthcare Global) a good stock to research?

Ans. HCG Oncology (Healthcare Global) has a PE of 50.00 and an ROE of 10.00%, with a D/E of 1.00 and a 52-week range of Rs 255.0 to Rs 430.0. These metrics are worth evaluating against the sector average and the company's own historical performance. Verify all data on NSE before investing.